… at the University of Cambridge in the United Kingdom, and Georgetown University and the National Institutes of Health in the United States. Scientists from the Netherlands, Italy and Spain also played key roles. The findings are published in …
Category: Parkinson’s Disease
Clinical trials are now being planned for Parkinson’s Disease patients in the USA
Cambridge scientists have discovered a naturally-occurring steroid that could be used as the basis of a revolutionary treatment for Parkinson’s Disease. Preliminary findings show the compound squalamine blocks a molecular process thought to underlie the disease and suppresses its toxic products.
Allergan continues to acquire companies
Allergan, the Ireland-based pharmaceutical giant with a plant in Waco scheduled to receive a $200 million expansion, continued a multimonth spending spree on Monday by announcing deals with smaller companies pursuing treatments for neurological disorders and diseases of the digestive tract. The company last year broke ground on a 322,000-square-foot addition to its Waco facility at 8301 Mars Drive, a move aimed at increasing manufacturing space that could create 100 full-time jobs in the near future and eventually 250 more when production approaches capacity.
Parkinson’s Disease, Movement Disorders Education & Support
Waldo County General Hospital Home Health Conference Room, 125 Northport Ave., Belfast. Group meets monthly and is for adults with Parkinson’s disease, their families and friends.
Experimental treatment shows early promise for improving Parkinson’s symptoms
About fourteen years ago, Bill Crawford noticed a persistent twitching in one of his fingers that was interfering with his rehearsal time as the music pastor at Porter Memorial Church. He’d noticed a few other things too, like weakness.
GYENNO’s Health Tech Solutions Help Parkinson’s Patients Maintain…
CES, Las Vegas, NV, Booth 43951, Tech West, Sands Expo, Level 2 – January 5, 2017 Health tech, big data and the Internet of Things come together in GYENNO Technologies. At CES, the company is showcasing unique solutions for the millions with Parkinson’s Disease and similar conditions to help them maintain independence, eat without embarrassment, and improve their gait problems, while also providing a wealth of data to assist researchers better understand the progress of the disease.
Mouse Study: Inactivity in Obesity May be Tied to Dopamine Receptors
… altered dopamine receptors rather than excess body fat. “We know that physical activity is linked to overall good health, but not much is known about why people or animals with obesity are less active,” said the study’s senior author, Dr. Alexxai V. …
Simple breath test can detect cancer and 16 other diseases
Ancient Greek physicians figured that our breath was a strong health indicator , but researchers from the Israel Institute of Technology have proven just how true that is. They developed a device that uses nanoparticles to identify 17 different diseases, including lung cancer and Parkinson’s disease, from just a single breath.
GBA Variants Influence Motor and Non-Motor Features of Parkinson’s Disease.
To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. The presence of mutations in glucocerebrosidase gene is a known factor increasing the risk of developing Parkinson’s disease .
Aggregated Alpha-Synuclein Transfer Efficiently between Cultured…
To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. Parkinson’s disease and other alpha-synucleinopathies are progressive neurodegenerative diseases characterized by aggregates of misfolded alpha-synuclein spreading throughout the brain.
Opicapone as levodopa adjunct cuts motor fluctuations in Parkinson’s disease
For patients with Parkinson’s disease receiving levodopa therapy and experiencing end-of-dose motor fluctuations, treatment with 50-mg/day opicapone is associated with a reduction in mean daily off-time, according to a study published online Dec. 27 in JAMA Neurology . Andrew J. Lees, M.D., from University College London, and colleagues enrolled 427 patients with PD receiving levodopa therapy who experienced signs of end-of-dose deterioration into a phase 3 trial.
NeuroDerm advances mid-stage study of ND0612H in Parkinson’s; shares ahead 4%
NeuroDerm announces the completion of enrollment and treatment in its 38-subject Phase 2 clinical trial assessing ND0612H in patients suffering from advanced Parkinson’s disease . The study is evaluating two dosing regimens of the high dose version of ND0612 compared with baseline oral standard of care.
Achat Generique Artane a ” Livraison rapide
Ou ordonner Trihexyphenidyl a prix reduit. For decades, Generic Artane has been helping to alleviate pain caused by Parkinson’s disease.